Biogen Inc. (BIIB) stock surged 8.47% in pre-market trading on Wednesday, despite the drugmaker forecasting 2025 profit below Wall Street expectations. The company's shares were bolstered by a new research and development (R&D) funding deal for its potential lupus treatment.
Biogen projected 2025 revenue to decline by a mid-single digit percentage from 2024 levels, excluding currency fluctuations. The company's adjusted 2025 profit outlook of $15.25 to $16.25 per share fell short of analysts' estimates of $16.34, weighed down by a strong dollar and fierce competition for its multiple sclerosis drugs.
However, Biogen's fortunes received a boost from its collaboration with Royalty Pharma, where the latter agreed to provide up to $250 million in R&D funding for Biogen's investigational drug litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. Litifilimab demonstrated proof-of-concept and a generally well-tolerated safety profile in systemic and cutaneous lupus erythematosus, with results published in the New England Journal of Medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.